showed a trendP =0.08
Two RCTs showed similar efficacy between EBL and EVO for treating GOV1 bleeding [ 201 , 231 ], another RCT showed a trend toward higher hemostasis rate in the EVO group compared to the EBL group (85% vs. 43%, P =0.08) [ 44 ].
Two RCTs showed similar efficacy between EBL and EVO for treating GOV1 bleeding [ 201 , 231 ], another RCT showed a trend toward higher hemostasis rate in the EVO group compared to the EBL group (85% vs. 43%, P =0.08) [ 44 ].